睿智醫藥(300149.SZ):2024年度預虧1.93億元–2.5億元
格隆匯1月24日丨睿智醫藥(300149.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤虧損1.93億元–2.5億元,扣除非經常性損益後的淨利潤虧損2億元–2.6億元。
2024年度,因持續受市場需求變化等多方面因素的影響,公司全資子公司上海睿智醫藥研究集團有限公司經營業績未達預期,商譽出現減值跡象,結合實際經營情況,根據《企業會計準則第8號–資產減值》及相關會計政策規定,公司基於謹慎性原則,預計本期將對收購上海睿智形成的商譽和長期資產計提減值金額為12,000萬元至13,926萬元人民幣。2024年度最終商譽和長期資產減值計提的金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。
2024年,預計非經常性損益對公司淨利潤的影響金額約700萬元-1,000萬元,主要是計入當期損益的政府補助、非流動性資產處置損益等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.